Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study

Vaishali Sanchorawala*, Giovanni Palladini, Monique C. Minnema, Arnaud Jaccard, Hans C. Lee, Simon Gibbs, Peter Mollee, Christopher Venner, Jin Lu, Stefan Schönland, Moshe Gatt, Kenshi Suzuki, Kihyun Kim, María Teresa Cibeira, Meral Beksac, Edward Libby, Jason Valent, Vania Hungria, Sandy W. Wong, Michael RosenzweigNaresh Bumma, Dominique Chauveau, Katharine S. Gries, John Fastenau, Nam Phuong Tran, Xiang Qin, Sandra Y. Vasey, Brendan M. Weiss, Jessica Vermeulen, Kai Fai Ho, Giampaolo Merlini, Raymond L. Comenzo, Efstathios Kastritis, Ashutosh D. Wechalekar

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Fingerprint

Dive into the research topics of 'Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study'. Together they form a unique fingerprint.

Medicine & Life Sciences